风华高科(000636) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥1,258,032,930.71, representing a year-on-year increase of 10.03%[4] - Net profit attributable to shareholders for the same period was ¥373,667,924.27, a significant increase of 305.40% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥241,439,603.31, up by 61.88% year-on-year[4] - The basic earnings per share for Q3 2021 was ¥0.42, which is an increase of 320.00% compared to the same period last year[4] - The weighted average return on net assets increased by 4.10 percentage points to 5.63%[4] - The company reported a significant increase in net profit for the year-to-date period, reaching ¥879,353,869.24, which is a 153.72% increase year-on-year[4] - Operating profit amounted to CNY 991,186,173.20, up 62.2% from CNY 610,605,831.35 year-on-year[31] - Net profit for the period was CNY 884,876,268.15, representing a significant increase of 148.5% compared to CNY 356,852,879.11 in the same period last year[31] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥10,223,043,466.13, reflecting a growth of 16.45% from the end of the previous year[6] - The company's total equity attributable to shareholders was ¥6,818,580,602.45, up by 13.92% from the previous year[6] - As of September 30, 2021, the company's total assets reached approximately CNY 10.22 billion, an increase from CNY 8.78 billion at the end of 2020, representing a growth of about 16.3%[21] - The company's long-term equity investments increased to CNY 626.26 million from CNY 588.89 million, marking a growth of approximately 6.3%[23] - The total current liabilities decreased slightly to CNY 2.06 billion from CNY 2.09 billion, a reduction of about 1.4%[23] - The company’s total liabilities decreased to CNY 3.36 billion from CNY 3.45 billion, a reduction of approximately 2.6%[23] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥693,155,448.92, showing a growth of 104.47%[4] - Cash flow from operating activities increased by 104.47% to CNY 693,155,448.92 compared to CNY 339,003,234.97 in the previous year[13] - Operating cash inflow for the current period reached CNY 3,336,376,002.73, a 34.8% increase from CNY 2,472,139,960.88 in the previous period[39] - Cash outflow from investing activities totaled CNY 1,489,436,726.89, significantly higher than CNY 890,708,536.48 in the previous period, resulting in a net cash flow from investing activities of -CNY 1,414,166,936.24[39] - Cash inflow from financing activities was CNY 1,658,267,776.11, compared to CNY 709,000,000.00 in the previous period, indicating a substantial increase[41] Research and Development - Research and development expenses increased by 53.79% to CNY 205,239,040.84 from CNY 133,454,680.64 year-on-year, reflecting the company's commitment to enhancing product competitiveness[11] - Research and development expenses increased to CNY 205,239,040.84, up 53.7% from CNY 133,454,680.64 in the previous year[31] Inventory and Receivables - The company's inventory increased by 41.46% to CNY 718,377,869.00, driven by increased orders and proactive material procurement[11] - The company’s accounts receivable decreased to CNY 826.94 million from CNY 939.00 million, a decline of approximately 11.9%[21] - The total amount of other receivables surged by 1,784.94% to CNY 301,764,558.91, primarily due to the exclusion of a subsidiary from the consolidation scope[11] Future Plans - The company plans to continue expanding its production capacity and investing in new technologies to enhance market competitiveness[12] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[31] Financial Health - The financial results indicate a strong recovery and growth trajectory, positioning the company favorably for upcoming quarters[31]